Genetico Center (Genetics and Reproductive Medicine Center, MOEX: GECO) published an analytical review of the global next generation sequencing (NGS) markets.
In 2022, the global NGS market was estimated at $9.71 billion with a compound annual growth rate (CAGR) of 17.1%. At this growth rate, the global NGS research market is expected to reach $25.03 billion by 2028.
Next Generation Sequencing (NGS) is a genome deciphering technology. Today, NGS-based research is used in clinical practice to find the causes of diseases at the gene level, clarify the diagnosis and prognosis of the disease course (especially in complex cases), and select effective therapy. Diagnostic NGS testing is included in clinical guidelines for ASD (Autism Spectrum Disorder) and epilepsy. However, NGS research for scientific and academic purposes accounts for about 55% of the market, which amounts to approximately $5.24 billion globally in 2022, whereas clinical practice research accounts for about $2.43 billion.
According to analytical data, the NGS research market in the United States reached $2.2 billion by 2022, with a potential to grow to $5.62 billion by 2028.
The Chinese market could reach approximately $1.23 billion in 2022. By 2028, the NGS research market in China is expected to reach $3.03 billion.
The UK market is estimated at approximately $0.535 billion in 2022 and can reach approximately $1.28 billion by 2028.
According to Genetico Center’s calculations based on publicly available data, published information on government procurement and other available information, the Russian NGS research market in 2022 amounted to approximately $0.014 billion (RUB 1,055 million). Today, the market mostly consists of scientific research, including research under scientific grants (about RUB 650 million). The share of clinical trials amounted to about RUB 400 million.
In the longer term, the following main demand drivers can be identified in Russia:
Genetico Center (Genetics and Reproductive Medicine Center, MOEX: GECO), a resident of Skolkovo, Technopark Medtech, an Artgen Biotech Group company (ex. Human Stem Cell Institute, MOEX: ABIO). Genetico works in the field of medical genetics and genetic research, implementing into medical practice innovative solutions for the diagnosis, prevention, and treatment of genetic and socially significant diseases.
Genetico’s developments focus on socially significant diseases and reproductive medicine. Genetico implements advanced NGS genetic analysis technologies and develops its own NGS panels for screening and genetic diagnosis of hereditary diseases for reproductive medicine and oncology.
On April 25, 2023, Genetico conducted an IPO on the Moscow Exchange. The order book was oversubscribed by 2.5 times. It was the first IPO in the Russian market this year. The Moscow Exchange listed Genetico’s shares as high-tech economy sector securities.
For the full version of the analytical report, go to: https://investors.genetico.ru/overview%20of%20international%20NGS%20markets.html